Navigation Links
Escalon(R) Reports First Quarter Fiscal 2009 Results
Date:11/13/2008

s are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:
-- implement its growth and marketing strategies, improve upon the

operations of the Company business units, including the ability to make

acquisitions and the integration of any acquisitions it may undertake,

if any, of which there can be no assurance,

-- implement cost reductions,

-- generate cash,

-- identify, finance and enter into business relationships and

acquisitions

-- new product development, commercialization, manufacturing and market

acceptance of new products,.

Other factors include uncertainties and risks related to:

-- marketing acceptance of existing products in new markets,

-- research and development activities, including failure to demonstrate

clinical efficacy,

-- delays by regulatory authorities, scientific and technical advances by

the Company or third parties,

-- introduction of competitive products,

-- ability to reduce staffing and other costs and retain benefit of prior

reductions

-- third party reimbursement and physician training, and

-- general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in the Company's report on Form 10-K for year ended June 30, 2008, and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.

-Financial Tables Follow-

ESCALON MEDICAL CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

For the Three Months Ended September 30, 2008 2007

Net revenues:

Produ
'/>"/>

SOURCE Escalon Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
2. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
3. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
4. Escalon(R) Announces Executive Promotions
5. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
6. Escalon(R) Reports First Quarter Fiscal 2008 Results
7. Escalon(R) Reports Financial Results for 2007 Fiscal Year
8. PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer
9. PA Health Department Reports Southeast Regions First Lab-Confirmed Influenza Case of the Season
10. CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions
11. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The regional economy is about to ... on the grow again. The plant will invest ... to boost production of the popular Highlander midsize sport ... investment to $4 billion. This step allows Toyota to ... flexibility to adjust its product mix to meet changing ...
(Date:8/22/2014)... News) -- Many Americans know little about how Ebola is ... outbreak in the United States, a new survey shows. ... there will be a major Ebola outbreak in the United ... family member will get sick with the deadly virus in ... Public Health poll. However, those opinions don,t match reality, ...
(Date:8/22/2014)... August 22, 2014 Beat Eczema ... they can use natural methods to completely cure the ... the attention of Shane Michaels, prompting an investigative review. ... affects the skin, it can still be extremely debilitating ... Michaels. “The intense itching and pain that it causes ...
(Date:8/22/2014)... (EGFR) mutations found in the circulating free tumor DNA ... cancer (NSCLC) patients correlates well with the EGFR mutations ... inhibitor (TKI) therapy is approved for EGFR activating mutation ... determining mutation status is with DNA derived directly from ... A more abundant and less invasive source of tumor ...
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
Breaking Medicine News(10 mins):Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3
... New studies at the University of Adelaide, Australia, will delve ... tumours and stroke. , The research, to be conducted in ... aim to find links between chemical signals in the brain ... , There are still many mysteries around how the brain ...
... Perfect" Score by the American Correctional Association Auditors ... Earns High Praise From Board Chair Romanowicz, ... an exhaustive,three-day audit and examination by the American Correctional ... pleased to report that the Donald W. Wyatt Detention,Facility ...
... Companies align,commercial and portfolio management employees by therapeutic ... of $10 to 20 billion, on average nine,marketing ... along,with approximately eight portfolio managers. At companies with ... three, commercial to,portfolio management staff, according to a ...
... and Other Ethnic Minorities at Increased Risk, BALTIMORE, ... J.,Barthelow Classen in The Open Endocrinology Journal shows a ... following the,discontinuation of a single vaccine, a vaccine to ... is a global epidemic of type 2,diabetes and metabolic ...
... are five-to-six times more likely to be at serious risk ... early as their teenage years, according to a new study ... Hill. , The findings, published Friday (April 4) in the ... children twice first while in grade school, then again ...
... at Ralphs Pharmacies Throughout Southern California, LOS ANGELES, ... pharmacy customers generic drugs for $4 per prescription at,its ... apply to hundreds of generic drugs prescribed for,30-day supplies ... stores,throughout Southern California. A list of the participating pharmacies ...
Cached Medicine News:Health News:Unlocking mysteries of brain cancer, stroke 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 2Health News:Donald W. Wyatt Detention Facility Scores 3-Year Accreditation and Among Highest Rated in the United States 3Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome 2Health News:Inactive kids face 6-fold risk of heart disease by teen years, study finds 2Health News:Ralphs Introduces $4 Generic Drugs 2
(Date:8/22/2014)... 2014 /CNW/ - On Aug. 20, at its annual ... Medical Association (CMA) voted on and approved a delegate ... medicinal cannabis. Bedrocan Cannabis Corp., a leading Canadian licensed ... motion. The CMA is quite right to ... smoking any plant material, including medicinal cannabis. While some ...
(Date:8/22/2014)... , Aug. 22, 2014  Dr. Mark ... with the Diamond Lifetime Achievement Award in the field ... CEO of Cardiovascular Clinical Associates. Dr. Rasak ... managing all major aspects of the business; overseeing the ... as primary coronary intervention. In addition, he is an ...
(Date:8/22/2014)... Research and Markets has announced ... Catheter Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Global and Chinese Intravenous Catheter Industry Report 2014 2
... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
... WIRE)--May 24, 2007 - Inovio Biomedical,Corporation (AMEX:INO), ... for cancers and infectious diseases and a ... announced today,that interim clinical trial results demonstrated ... technology was,safe and tolerable, facilitated gene expression, ...
Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 2Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 3Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 4Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 5
... on patented microplate agglutination technology. Its is ... donor ABO/Rh testing. PK7200 also handles weak ... antibody detection. The Automated Microplate System delivers ... proven reliability that for the past generation ...
... Tecan Haemotyper is an automated ... The Tecan Haemotyper combines a ... platform with the DiaMed agglutination ... process DiaMed-ID cards and microplates ...
... 1990s, the "Reversed" shoulder prosthesis has been ... success. More recently, an ever-growing number of ... to champion this prosthesis and the associated ... reversed technology is the result of nearly ...
Inquire...
Medicine Products: